Safety of zonisamide therapy: prospective follow-up survey

Area of Science:

• Neurology
• Pharmacovigilance

Background:

• Zonisamide is an antiepileptic drug (AED) used for various seizure types.
• Postmarketing surveillance is crucial for evaluating long-term drug safety in real-world patient populations.

Purpose of the Study:

• To evaluate the safety and tolerability of zonisamide in a large cohort of pediatric and adult patients with epilepsy.
• To compare the incidence of adverse events between zonisamide monotherapy and polytherapy.

Main Methods:

• A postmarketing surveillance study involving 1512 patients (1 month to 79 years) treated with zonisamide for 1-3 years.
• Data collection on adverse events, including type, incidence, and patient demographics (age, monotherapy vs. polytherapy).

Main Results:

• Overall adverse event incidence was 31.5% (476/1512).
• Monotherapy (21%) had significantly lower adverse events than polytherapy (35.6%).
• Children (26.2%) experienced fewer adverse events than adults (39.9%). Common events included psychiatric, gastrointestinal, and neurological symptoms. Unique effects noted were mental function impairment and hypohidrosis. Urinary calculi were rare (0.13%). Limited teratogenicity data showed mostly normal outcomes, but one case of fetal malformation occurred with polytherapy.

Conclusions:

• Zonisamide appears safer as monotherapy compared to polytherapy for epilepsy treatment.
• Children generally tolerate zonisamide better than adults.
• While zonisamide has a manageable safety profile, potential psychiatric effects, hypohidrosis, and rare teratogenic risks warrant consideration, especially in polytherapy regimens.